Abstract
Cisplatin is a chemotherapeutic coordination complex that has been evaluated extensively. It is particularly active against testicular cancer, but carcinomas of the ovary, bladder, cervix, and head and neck are also responsive. To increase efficacy and decrease toxicity, a number of platinum analogues have been developed and tested. One of these, carboplatin, is of particular interest. In clinical trials, it has demonstrated antitumor activity comparable to that of cisplatin, without evidence of significant renal toxicity or neurotoxicity. A second interesting platinum analogue is iproplatin. Preliminary phase I studies suggest reduced adverse renal and neurologic effects similar to those seen with carboplatin, with efficacy comparable to cisplatin. Attempts to overcome the dose-limiting toxicity of cisplatin by administering high-dose cisplatin (40 mg/m2/d for five days) in hypertonic saline or with thiosulfate protection are also reviewed. These techniques have eliminated nephrotoxicity as the dose-limiting toxicity of cisplatin. However, nonrenal toxicity, especially neurotoxicity, remains substantial. The extent to which high-dose cisplatin-based chemotherapy should be used in routine clinical practice has not been determined.
References
Feb 8, 1979·The New England Journal of Medicine·L H Einhorn, S D Williams
Sep 1, 1985·Cancer Treatment Reviews·M J PeckhamW F Hendry
Sep 1, 1985·Cancer Treatment Reviews·I E Smith, B D Evans
Sep 1, 1988·European Journal of Cancer & Clinical Oncology·H AndersonP Palmer
Sep 1, 1985·Cancer Treatment Reviews·J G McVieI Klein
Sep 1, 1985·Cancer Treatment Reviews·E Wiltshaw
Feb 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C E PfeifleM P Murphy
Jan 1, 1984·Annals of Internal Medicine·R F OzolsR C Young
Mar 1, 1984·Cancer·M K SamsonG D Cummings
May 1, 1984·Annals of Internal Medicine·P J Loehrer, L H Einhorn
Aug 1, 1984·European Journal of Cancer & Clinical Oncology·P LelieveldA Danguy
Jan 1, 1984·Advances in Pharmacology and Chemotherapy·J M VendittiJ Plowman
Dec 1, 1982·Annals of Internal Medicine·S B HowellM Green
Aug 1, 1982·Journal of Medicinal Chemistry·D B BrownD Frost
Oct 15, 1980·Cancer·S OstrowP H Wiernik
Aug 1, 1981·Gynecologic Oncology·H W BrucknerJ F Holland
Oct 1, 1981·Toxicology and Applied Pharmacology·C L Litterst
Dec 1, 1981·British Journal of Obstetrics and Gynaecology·G H Barker, E Wiltshaw
Citations
May 15, 1991·Biochemical Pharmacology·G S BaldewN P Vermeulen
Jul 22, 1992·Biochemical Pharmacology·G S BaldewN P Vermeulen
Jan 1, 1994·Cancer Investigation·D Rideout
Aug 28, 2009·European Journal of Cancer Care·A P GreystokeM J Mackean
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F P HarmersJ P Neijt
May 28, 2002·Cancer Biotherapy & Radiopharmaceuticals·R P GudeA G Jagtap
May 15, 1990·International Journal of Cancer. Journal International Du Cancer·H KobayashiT Baba
Jun 13, 2017·Chemical Reviews·Fan HongHao Yan
Nov 10, 2018·ACS Omega·Eva Villar-AlvarezVíctor Mosquera
Jul 19, 2012·Journal of the American Chemical Society·Qiao JiangBaoquan Ding